ATC Group: D04AB01 Lidocaine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of D04AB01 in the ATC hierarchy

Level Code Title
1 D Dermatologicals
2 D04 Antipruritics, incl. antihistamines, anesthetics, etc.
3 D04A Antipruritics, incl. antihistamines, anesthetics, etc.
4 D04AB Anesthetics for topical use
5 D04AB01 Lidocaine

Active ingredients in D04AB01

Active Ingredient Description
Lidocaine

Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane.

Related product monographs

Title Information Source Document Type  
LMX4 Cream Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
STUD 100 Marketing Authorisation Holder MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

  • (combination) EMLA

Brazil (BR)

  • (combination) EMLA

Canada (CA)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

  • (combination) EMLA

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

  • (combination) EMLA

Lithuania (LT)

Malta (MT)

  • (combination) EMLA

Mexico (MX)

  • (combination) EMLA

Netherlands (NL)

  • (combination) EMLA

New Zealand (NZ)

Nigeria (NG)

Poland (PL)

Singapore (SG)

South Africa (ZA)

  • (combination) EMLA

Spain (ES)

Tunisia (TN)

  • (combination) EMLA

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.